Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6P093
UPID:
ADCL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q6P093; Q5HYJ4
Background:
Arylacetamide deacetylase-like 2, encoded by the gene with the accession number Q6P093, plays a crucial role in the metabolism of various substances within the body. Its specific functions and interactions within cellular processes are subjects of ongoing research, highlighting its potential importance in biological systems.
Therapeutic significance:
Understanding the role of Arylacetamide deacetylase-like 2 could open doors to potential therapeutic strategies. Its involvement in metabolic pathways suggests a possible link to disease mechanisms, making it a target of interest for drug discovery efforts aimed at modulating its activity for therapeutic benefits.